Skip to main content Skip to section navigation Skip to footer
SCYNEXIS, Inc. SCYNEXIS, Inc.
  • About Us
    • Our Mission
    • Leadership
    • Partnerships
    • Careers
    • Contact Us
  • Our Science
    • Ibrexafungerp
    • Life-threatening Infections
    • Community Infections
    • Pipeline
    • Publications and Presentations
  • Our Product
  • News
    • News
    • Events
  • Careers
  • Investors
    • News & Events
    • Company Info
    • Financial Info
    • Stock Info
    • SEC Filings
    • Governance

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Leadership
    • Contacts
    • FAQ
    • Tear Sheet
  • Financial Info
    • Overview
    • Financial Results
    • Key Ratios
    • Investor Calculator
  • Stock Info
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Investor Calculator
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Filings
    • Quarterly Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Email Alerts
Mar 30, 2023 7:05am EDT

GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

Dec 01, 2022 8:00am EST

SCYNEXIS Announces FDA Approval of Second Indication for BREXAFEMME® (ibrexafungerp tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Nov 30, 2022 8:30am EST

SCYNEXIS Announces $3 Million National Institutes of Health Grant Has Been Awarded to Case Western Reserve University Researchers to Study Second Generation Fungerp (SCY-247) to Fight Drug-Resistant Fungi

Nov 17, 2022 8:30am EST

SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats

Nov 09, 2022 7:00am EST

SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 07, 2022 8:30am EST

SCYNEXIS Announces Publication of Review Article Highlighting Ibrexafungerp as a Potential Novel Treatment for Invasive Mold Infections in the Journal of Fungi

Nov 03, 2022 8:30am EDT

Pooled Data from the Pivotal Phase 3 VANISH Program Published in the Journal of Women’s Health Demonstrate Significant Efficacy of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection

Nov 01, 2022 8:30am EDT

SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

Oct 25, 2022 8:30am EDT

Biopharma Veteran Ivor Macleod Joins SCYNEXIS as Chief Financial Officer

Oct 24, 2022 8:30am EDT

SCYNEXIS Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 35
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
Scynexis
1 Evertrust Plaza, Jersey City, NJ 07302
(201) 884-5485
Facebook Twitter Linkedin
  • Patents
  • Expanded Access
  • Privacy Policy
  • Disclaimer
  • Sitemap
© 2025 SCYNEXIS, Inc. All Rights Reserved.